Secretin

Secretin is a hormone that regulates water homeostasis throughout the body and influences the environment of the duodenum by regulating secretions in the stomach, pancreas, and liver. It is a peptide hormone produced in the S cells of the duodenum, which are located in the intestinal glands.[3] In humans, the secretin peptide is encoded by the SCT gene.[4]

SCT
Identifiers
AliasesSCT, entrez:6343
External IDsOMIM: 182099 HomoloGene: 137358 GeneCards: SCT
Gene location (Human)
Chr.Chromosome 11 (human)[1]
Band11p15.5Start626,309 bp[1]
End627,181 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

6343

n/a

Ensembl

ENSG00000070031
ENSG00000274473

n/a

UniProt

P09683

n/a

RefSeq (mRNA)

NM_021920

n/a

RefSeq (protein)

NP_068739

n/a

Location (UCSC)Chr 11: 0.63 – 0.63 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Secretin helps regulate the pH of the duodenum by (1) inhibiting the secretion of gastric acid from the parietal cells of the stomach and (2) stimulating the production of bicarbonate from the ductal cells of the pancreas.[5][6] It also stimulates bile production by the liver; the bile emulsifies dietary fats in the duodenum so that pancreatic lipase can act upon them. Meanwhile, in concert with secretin's actions, the other main hormone simultaneously issued by the duodenum, cholecystokinin (CCK), is stimulating the gallbladder to contract, delivering its stored bile for the same reason.

Prosecretin is a precursor to secretin, which is present in digestion. Secretin is stored in this unusable form, and is activated by gastric acid. This indirectly results in the neutralisation of duodenal pH, thus ensuring no damage is done to the small intestine by the aforementioned acid.[7]

In 2007, secretin was discovered to play a role in osmoregulation by acting on the hypothalamus, pituitary gland, and kidney.[8][9]

Discovery

Secretin was the first hormone to be identified.[10] In 1902, William Bayliss and Ernest Starling were studying how the nervous system controls the process of digestion.[11] It was known that the pancreas secreted digestive juices in response to the passage of food (chyme) through the pyloric sphincter into the duodenum. They discovered (by cutting all the nerves to the pancreas in their experimental animals) that this process was not, in fact, governed by the nervous system. They determined that a substance secreted by the intestinal lining stimulates the pancreas after being transported via the bloodstream. They named this intestinal secretion secretin. Secretin was the first such "chemical messenger" identified. This type of substance is now called a hormone, a term coined by Starling in 1905.[12]

Structure

Secretin is initially synthesized as a 120 amino acid precursor protein known as prosecretin. This precursor contains an N-terminal signal peptide, spacer, secretin itself (residues 28–54), and a 72-amino acid C-terminal peptide.[4]

The mature secretin peptide is a linear peptide hormone, which is composed of 27 amino acids and has a molecular weight of 3055. A helix is formed in the amino acids between positions 5 and 13. The amino acids sequences of secretin have some similarities to that of glucagon, vasoactive intestinal peptide (VIP), and gastric inhibitory peptide (GIP). Fourteen of 27 amino acids of secretin reside in the same positions as in glucagon, 7 the same as in VIP, and 10 the same as in GIP.[13]

Secretin also has an amidated carboxyl-terminal amino acid which is valine.[14] The sequence of amino acids in secretin is H–His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val–NH2.[14]

Physiology

Production and secretion

Secretin is synthesized in cytoplasmic secretory granules of S-cells, which are found mainly in the mucosa of the duodenum, and in smaller numbers in the jejunum of the small intestine.[15]

Secretin is released into circulation and/or intestinal lumen in response to low duodenal pH that ranges between 2 and 4.5 depending on species; the acidity is due to hydrochloric acid in the chyme that enters the duodenum from the stomach via the pyloric sphincter.[16] Also, the secretion of secretin is increased by the products of protein digestion bathing the mucosa of the upper small intestine.[17]

Secretin release is inhibited by H2 antagonists, which reduce gastric acid secretion. As a result, if the pH in the duodenum increases above 4.5, secretin cannot be released.[18]

pH regulation

Secretin primarily functions to neutralize the pH in the duodenum, allowing digestive enzymes from the pancreas (e.g., pancreatic amylase and pancreatic lipase) to function optimally.[19]

Secretin targets the pancreas; pancreatic centroacinar cells have secretin receptors in their plasma membrane. As secretin binds to these receptors, it stimulates adenylate cyclase activity and converts ATP to cyclic AMP.[20] Cyclic AMP acts as second messenger in intracellular signal transduction and causes the organ to secrete a bicarbonate-rich fluid that flows into the intestine. Bicarbonate is a base that neutralizes the acid, thus establishing a pH favorable to the action of other digestive enzymes in the small intestine.[21]

Secretin also increases water and bicarbonate secretion from duodenal Brunner's glands to buffer the incoming protons of the acidic chyme,[19] and also reduces acid secretion by parietal cells of the stomach.[22] It does this through at least three mechanisms: 1) By stimulating release of somatostatin, 2) By inhibiting release of gastrin in the pyloric antrum, and 3) By direct downregulation of the parietal cell acid secretory mechanics.[23][16]

It counteracts blood glucose concentration spikes by triggering increased insulin release from pancreas, following oral glucose intake.[24]

Osmoregulation

Secretin modulates water and electrolyte transport in pancreatic duct cells,[25] liver cholangiocytes,[26] and epididymis epithelial cells.[27] It is found[28] to play a role in the vasopressin-independent regulation of renal water reabsorption.[8]

Secretin is found in the magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus and along the neurohypophysial tract to neurohypophysis. During increased osmolality, it is released from the posterior pituitary. In the hypothalamus, it activates vasopressin release.[9] It is also needed to carry out the central effects of angiotensin II. In the absence of secretin or its receptor in the gene knockout animals, central injection of angiotensin II was unable to stimulate water intake and vasopressin release.[29]

It has been suggested that abnormalities in such secretin release could explain the abnormalities underlying type D syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH).[9] In these individuals, vasopressin release and response are normal, although abnormal renal expression, translocation of aquaporin 2, or both are found.[9] It has been suggested that "Secretin as a neurosecretory hormone from the posterior pituitary, therefore, could be the long-sought vasopressin independent mechanism to solve the riddle that has puzzled clinicians and physiologists for decades."[9]

Food intake

Secretin and its receptor are found in discrete nuclei of the hypothalamus, including the paraventricular nucleus and the arcuate nucleus, which are the primary brain sites for regulating body energy homeostasis. It was found that both central and peripheral injection of Sct reduce food intake in mouse, indicating an anorectic role of the peptide. This function of the peptide is mediated by the central melanocortin system.[30]

Uses

Secretin is used in a diagnostic tests for pancreatic function; secretin is injected and the pancreatic output can then be imaged with magnetic resonance imaging, a noninvasive procedure, or secretions generated as a result can gathered either through an endoscope or through tubes inserted through the mouth, down into the duodenum.[31][32][33]

A recombinant human secretin has been available since 2004 for these diagnostic purposes.[34] There were problems with the availability of this agent from 2012 to 2015.[35]

Research

A wave of enthusiasm for secretin as a possible treatment for autism arose in the 1990s based on a hypothetical gut-brain connection; as a result the NIH ran a series of clinical trials that showed that secretin was not effective, which brought an end to popular interest.[36][37][38]

A high-affinity and optimized secretin receptor antagonist (Y10,c[E16,K20],I17,Cha22,R25)sec(6-27) has been designed and developed which has allowed the structural characterization of secreting inactive conformation.[39]

See also

References
  1. ENSG00000274473 GRCh38: Ensembl release 89: ENSG00000070031, ENSG00000274473 - Ensembl, May 2017
  2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. Häcki WH (1980). "Secretin". Clinics in Gastroenterology. 9 (3): 609–32. PMID 7000396.
  4. Kopin AS, Wheeler MB, Leiter AB (1990). "Secretin: structure of the precursor and tissue distribution of the mRNA". Proceedings of the National Academy of Sciences of the United States of America. 87 (6): 2299–303. Bibcode:1990PNAS...87.2299K. doi:10.1073/pnas.87.6.2299. JSTOR 2354038. PMC 53674. PMID 2315322.
  5. Whitmore TE, Holloway JL, Lofton-Day CE, Maurer MF, Chen L, Quinton TJ, Vincent JB, Scherer SW, Lok S (2000). "Human secretin (SCT): gene structure, chromosome location, and distribution of mRNA". Cytogenetics and Cell Genetics. 90 (1–2): 47–52. doi:10.1159/000015658. PMID 11060443. S2CID 12850155.
  6. 1947-, Costanzo, Linda S. (2006). Physiology (3rd ed.). Philadelphia, PA: Saunders Elsevier. ISBN 9781416023203. OCLC 62326921.CS1 maint: numeric names: authors list (link)
  7. Gafvelin G, Jörnvall H, Mutt V (Sep 1990). "Processing of prosecretin: isolation of a secretin precursor from porcine intestine" (PDF). Proceedings of the National Academy of Sciences of the United States of America. 87 (17): 6781–5. Bibcode:1990PNAS...87.6781G. doi:10.1073/pnas.87.17.6781. PMC 54621. PMID 2395872.
  8. Chu JY, Chung SC, Lam AK, Tam S, Chung SK, Chow BK (2007). "Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption". Molecular and Cellular Biology. 27 (7): 2499–511. doi:10.1128/MCB.01088-06. PMC 1899889. PMID 17283064.
  9. Chu JY, Lee LT, Lai CH, Vaudry H, Chan YS, Yung WH, Chow BK (2009). "Secretin as a neurohypophysial factor regulating body water homeostasis". Proceedings of the National Academy of Sciences of the United States of America. 106 (37): 15961–6. Bibcode:2009PNAS..10615961C. doi:10.1073/pnas.0903695106. JSTOR 40484830. PMC 2747226. PMID 19805236.
  10. Henriksen JH, Schaffalitzky de Muckadell OB (2002). "Sekretin - det første hormon" [Secretin--the first hormone]. Ugeskrift for Laeger (in Danish). 164 (3): 320–5. PMID 11816326. INIST:13419424.
  11. Bayliss WM, Starling EH (1902). "The mechanism of pancreatic secretion". The Journal of Physiology. 28 (5): 325–53. doi:10.1113/jphysiol.1902.sp000920. PMC 1540572. PMID 16992627.
  12. Hirst, BH (2004), "Secretin and the exposition of hormonal control", J Physiol, 560 (2): 339, doi:10.1113/jphysiol.2004.073056, PMC 1665254, PMID 15308687.
  13. Williams, Robert L. (1981). Textbook of Endocrinology. Philadelphia: Saunders. p. 697. ISBN 978-0-7216-9398-9.
  14. DeGroot, Leslie Jacob (1989). McGuigan, J. E. (ed.). Endocrinology. Philadelphia: Saunders. pp. 2748. ISBN 978-0-7216-2888-2.
  15. Polak JM, Coulling I, Bloom S, Pearse AG (1971). "Immunofluorescent localization of secretin and enteroglucagon in human intestinal mucosa". Scandinavian Journal of Gastroenterology. 6 (8): 739–44. doi:10.3109/00365527109179946. PMID 4945081.
  16. Frohman, Lawrence A.; Felig, Philip (2001). "Gastrointestinal Hormones and Carcinoid Syndrome". In Ghosh, P. K.; O'Dorisio, T. M. (eds.). Endocrinology & metabolism. New York: McGraw-Hill, Medical Pub. Div. pp. 1675–701. ISBN 978-0-07-022001-0.
  17. Ganong, William F. (2003). "Regulation of Gastrointestinal Function". Review of Medical Physiology (21st ed.). New York: McGraw-Hill, Medical Pub. Div. ISBN 978-0-07-140236-1.
  18. Rominger JM, Chey WY, Chang TM (1981). "Plasma secretin concentrations and gastric pH in healthy subjects and patients with digestive diseases". Digestive Diseases and Sciences. 26 (7): 591–7. doi:10.1007/BF01367670. PMID 7249893. S2CID 7039025.
  19. Hall, John E.; Guyton, Arthur C. (2006). Textbook of medical physiology. St. Louis, Mo: Elsevier Saunders. pp. 800–1. ISBN 978-0-7216-0240-0.
  20. Gardner, JD (1978). "Receptors and gastrointestinal hormones". In Sleisenger, MH; Fordtran, JS (eds.). Gastrointestinal Disease (2nd ed.). Philadelphia: WB Saunders Company. pp. 179–95.
  21. Osnes M, Hanssen LE, Flaten O, Myren J (1978). "Exocrine pancreatic secretion and immunoreactive secretin (IRS) release after intraduodenal instillation of bile in man". Gut. 19 (3): 180–4. doi:10.1136/gut.19.3.180. PMC 1411891. PMID 631638.
  22. Palmer, KR; Penman, ID (2010). "Alimentary track and pancreatic disease". In Colledge, NR; Walker, BR; Ralston, SH (eds.). Davidson's Principles and Practice of Medicine (20th ed.). Edinburgh: Churchill Livingstone. p. 844. ISBN 978-0-7020-3085-7.
  23. Boron, Walter F.; Boulpaep, Emile L. (2012). "Acid secretion". Medical Physiology (2nd ed.). Philadelphia: Saunders. p. 1352. ISBN 978-1-4377-1753-2.
  24. Kraegen EW, Chisholm DJ, Young JD, Lazarus L (1970). "The gastrointestinal stimulus to insulin release. II. A dual action of secretin". The Journal of Clinical Investigation. 49 (3): 524–9. doi:10.1172/JCI106262. PMC 322500. PMID 5415678.
  25. Villanger O, Veel T, Raeder MG (1995). "Secretin causes H+/HCO3- secretion from pig pancreatic ductules by vacuolar-type H(+)-adenosine triphosphatase". Gastroenterology. 108 (3): 850–9. doi:10.1016/0016-5085(95)90460-3. PMID 7875488.
  26. Marinelli RA, Pham L, Agre P, LaRusso NF (1997). "Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane. Evidence for a secretin-induced vesicular translocation of aquaporin-1". The Journal of Biological Chemistry. 272 (20): 12984–8. doi:10.1074/jbc.272.20.12984. PMID 9148905.
  27. Chow BK, Cheung KH, Tsang EM, Leung MC, Lee SM, Wong PY (2004). "Secretin controls anion secretion in the rat epididymis in an autocrine/paracrine fashion". Biology of Reproduction. 70 (6): 1594–9. doi:10.1095/biolreprod.103.024257. PMID 14749298.
  28. Cheng CY, Chu JY, Chow BK (2009). "Vasopressin-independent mechanisms in controlling water homeostasis". Journal of Molecular Endocrinology. 43 (3): 81–92. doi:10.1677/JME-08-0123. PMID 19318428.
  29. Lee VH, Lee LT, Chu JY, Lam IP, Siu FK, Vaudry H, Chow BK (2010). "An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II". FASEB Journal. 24 (12): 5024–32. doi:10.1096/fj.10-165399. PMC 2992369. PMID 20739612.
  30. Cheng CY, Chu JY, Chow BK (2011). "Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system". Neuropsychopharmacology. 36 (2): 459–71. doi:10.1038/npp.2010.178. PMC 3055665. PMID 20927047.
  31. Lieb, John-G (2008). "Pancreatic function testing: Here to stay for the 21st century". World Journal of Gastroenterology. 14 (20): 3149–58. doi:10.3748/WJG.14.3149. PMC 2712845. PMID 18506918.
  32. Domínguez Muñoz, J. Enrique (June 2010). "Diagnosis of chronic pancreatitis: Functional testing". Best Practice & Research Clinical Gastroenterology. 24 (3): 233–241. doi:10.1016/j.bpg.2010.03.008. PMID 20510825.
  33. "Secretin stimulation test". MedlinePlus Medical Encyclopedia. United States National Library of Medicine. Retrieved 2008-11-01.
  34. "Human Secretin". Patient Information Sheets. United States Food and Drug Administration. 2004-07-13. Archived from the original on May 11, 2009. Retrieved 2008-11-01.
  35. American Society of Health-System Pharmacists (5 August 2015). "Secretin Injection". Current Drug Shortage Bulletin.
  36. Stokstad, Erik (18 July 2008). "News this Week: Stalled Trial for Autism Highlights Dilemma of Alternative Treatments". Science. p. 324.
  37. "The Use of Secretin to Treat Autism". NIH News Alert. United States National Institutes of Health. 1998-10-16. Retrieved 2008-11-30.
  38. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW (1999). "Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder". The New England Journal of Medicine. 341 (24): 1801–6. doi:10.1056/NEJM199912093412404. PMID 10588965.
  39. Dong M, Harikumar KG, Raval SR, Milburn JE, Clark C, Alcala-Torano R, Mobarec JC, Reynolds CA, Ghirlanda G, Christopoulos A, Wootten D, Sexton PM, Miller, LJ (2020). "Rational development of a high-affinity secretin receptor antagonist". Biochemical Pharmacology. 177: 113929. doi:10.1016/j.bcp.2020.113929. PMC 7299832. PMID 32217097.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.